Why the study?
Despite advances in CAD treatment, patients with CCS remain at elevated risk of MACE due to residual cardiovascular risk across multiple pathogenetic pathways.
This review highlights the importance of identifying and targeting specific pathogenetic pathways to manage residual cardiovascular risk in patients with chronic coronary syndromes.
Answers are grounded in this paper and cite their sources.
May prompt residual risk assessment in CCS; leaves open optimal targeted strategies for prospective validation.
Chronic coronary syndrome (CCS), which encompasses a broad spectrum of clinical presentations of coronary artery disease (CAD), is the leading cause of morbidity and mortality worldwide. Recent guidelines for the management of CCS emphasize the dynamic nature of the CAD process, replacing the term "stable" with "chronic", as this disease is never truly "stable". Despite significant advances in the treatment of CAD, patients with CCS remain at an elevated risk of major cardiovascular events (MACE) due to the so-called residual cardiovascular risk. Several pathogenetic pathways (thrombotic, inflammatory, metabolic, and procedural) may distinctly contribute to the residual risk in individual patients and represent a potential target for newer preventive treatments. Identifying the level and type of residual cardiovascular risk is essential for selecting the most appropriate diagnostic tests and follow-up procedures. In addition, new management strategies and healthcare models could further support available treatments and lead to important prognostic benefits. This review aims to provide an overview of the diagnostic and therapeutic challenges in the management of patients with CCS and to promote more effective multidisciplinary care.
No takes yet. Share an insight, caveat, or question.
Giubilato et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: